This prospective observational study aims to evaluate intermediate clinical, renal, and functional outcomes in patients with heart failure with reduced ejection fraction treated with contemporary guideline-directed medical therapy over a 6 to 12 month follow-up period.
Age 18 years or older
Diagnosis of chronic HFrEF with LVEF ≤ 40% documented by echocardiography
Stable on or planned initiation of guideline-directed medical therapy
Ability to provide informed consent
- Acute decompensated heart failure requiring intravenous inotropes at enrollment
End-stage renal disease on dialysis
eGFR less than 20 mL/min/1.73 m² at baseline
Severe primary valvular disease requiring immediate intervention
Adult patients with chronic heart failure with reduced ejection fraction attending the Cardiovascular Department at Assiut University.
Cohort
Prospective
Not listed
Change in NYHA functional class
Change in New York Heart Association (NYHA) functional class from baseline to follow-up.
Change in KCCQ-12 score
Change in Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) total score from baseline to follow-up (range 0-100, higher scores indicate better health status).
Change in left ventricular ejection fraction
Change in left ventricular ejection fraction (LVEF) measured by echocardiography from baseline to follow-up.
Change in estimated glomerular filtration rate
Change in estimated glomerular filtration rate (eGFR) calculated by CKD-EPI equation from baseline to follow-up.
Rate of heart failure hospitalization
Number of heart failure-related hospital admissions during the follow-up period.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
